Protocol Title:  “A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer” NCI Version Date: 07/3/2019

Attention Sites:

There were formatting issues with the NRG-GY018 protocol document that was posted on on 7/29/19. The document has now been fixed.

Anyone who downloaded NRG-GY018 (PVD 7/3/2019) before 8/2/19 should re-download the document with the "Post Date" of 02-Aug-2019 to assure they have the correctly formatted version.

Please note that there were no changes made to the protocol content.


This message was sent to by
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Unsubscribe from all mailings Unsubscribe | Manage Subscription | Forward Email | Report Abuse

This is a Test Email only.
This message was sent for the sole purpose of testing a draft message.